$CRMD
CorMedix Inc. Stock $crmd

$crmd Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000121390024021585 Filed on March 12, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue		$0.00
YoY Change		-100.0%
Cost Of Revenue	$818.5K	$0.00
YoY Change		-100.0%
Gross Profit	-$818.5K	$0.00
YoY Change		-100.0%
Gross Profit Margin
Selling, General & Admin	$15.05M	$13.38M	$35.80M
YoY Change	97.75%	139.98%	78.96%
% of Gross Profit
Research & Development	$837.4K	$2.289M	$13.16M
YoY Change	-75.42%	-19.5%	23.18%
% of Gross Profit
Depreciation & Amortization	$21.83K	$18.67K	$70.76K
YoY Change	29.43%	-17.1%	-16.38%
% of Gross Profit
Operating Expenses	$15.89M	$15.67M	$48.96M
YoY Change	44.19%	86.12%	59.55%
Operating Profit	-$16.70M	-$15.67M	-$48.96M
YoY Change	51.62%	86.77%	59.87%
Interest Expense	$9.835K	$914.7K	$34.30K
YoY Change	12.07%	407.41%	29.35%
% of Operating Profit
Other Income/Expense, Net	$843.3K		$2.619M
YoY Change	87.43%		677.84%
Pretax Income	-$15.86M	-$14.75M	-$45.95M
YoY Change	50.1%	79.73%	51.7%
Income Tax	-$1.395M	$0.00
% Of Pretax Income
Net Earnings	-$14.47M	-$14.75M	-$46.30M
YoY Change	36.9%	79.73%	55.88%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.25		-$0.91
Diluted Earnings Per Share	-$0.25	-$0.26	-$0.91
COMMON SHARES
Basic Shares Outstanding	54.98M shares	54.81M shares	50.90M shares
Diluted Shares Outstanding	57.50M shares		50.90M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$58.55M	$76.03M	$76.03M
YoY Change	5.31%	29.32%	29.32%
Cash & Equivalents	$35.18M	$43.64M	$43.64M
Short-Term Investments	$23.37M	$32.39M	$32.39M
Other Short-Term Assets	$2.538M	$1.313M	$1.313M
YoY Change	114.96%	73.07%	73.07%
Inventory	$2.320M	$2.106M	$2.106M
Prepaid Expenses	$295.8K	$353.6K
Receivables
Other Receivables
Total Short-Term Assets	$63.41M	$79.45M	$79.45M
YoY Change	11.67%	33.42%	33.42%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.906M	$1.866M	$2.507M
YoY Change	18.54%	15.94%	5.1%
Goodwill
YoY Change
Intangibles		$0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets	$103.8K	$103.1K	$103.1K
YoY Change	1.46%	0.72%	0.72%
Total Long-Term Assets	$4.614M	$2.610M	$2.610M
YoY Change	88.15%	4.92%	4.92%
TOTAL ASSETS
Total Short-Term Assets	$63.41M	$79.45M	$79.45M
Total Long-Term Assets	$4.614M	$2.610M	$2.610M
Total Assets	$68.02M	$82.06M	$82.06M
YoY Change	14.84%	32.27%	32.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.826M	$4.280M	$4.280M
YoY Change	95.38%	94.34%	94.34%
Accrued Expenses	$6.553M	$6.970M	$7.121M
YoY Change	112.13%	75.4%	73.31%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$9.534M	$11.40M	$11.40M
YoY Change	103.97%	80.65%	80.65%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$476.6K	$517.0K	$517.0K
YoY Change	-24.52%	-22.56%	-22.56%
Total Long-Term Liabilities	$476.6K	$517.0K	$517.0K
YoY Change	-24.52%	-22.56%	-22.56%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.534M	$11.40M	$11.40M
Total Long-Term Liabilities	$476.6K	$517.0K	$517.0K
Total Liabilities	$10.01M	$11.92M	$11.92M
YoY Change	88.68%	70.77%	70.77%
SHAREHOLDERS EQUITY
Retained Earnings	-$336.2M	-$321.7M
YoY Change	17.57%	16.83%
Common Stock	$54.96K	$54.94K
YoY Change	23.5%	28.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$58.01M	$70.14M	$70.14M
YoY Change
Total Liabilities & Shareholders Equity	$68.02M	$82.06M	$82.06M
YoY Change	14.84%	32.27%	32.27%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$14.47M	-$14.75M	-$46.30M
YoY Change	36.9%	79.73%	55.88%
Depreciation, Depletion And Amortization	$21.83K	$18.67K	$70.76K
YoY Change	29.43%	-17.1%	-16.38%
Cash From Operating Activities	-$17.31M	-$10.75M	-$38.41M
YoY Change	66.54%	74.59%	57.7%
INVESTING ACTIVITIES
Capital Expenditures	$61.31K	$295.9K	$327.3K
YoY Change	315.18%	129.85%	49.21%
Acquisitions
YoY Change
Other Investing Activities	$9.006M	$893.7K	-$16.73M
YoY Change	-161.38%	604.27%	379.5%
Cash From Investing Activities	$8.945M	$597.8K	-$17.06M
YoY Change	-160.9%	-32239.25%	359.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$12.95M
YoY Change			-27.13%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$97.12K	467.6K	$55.92M
YoY Change	-101.35%	-92.26%	212.42%
NET CHANGE
Cash From Operating Activities	-$17.31M	-10.75M	-$38.41M
Cash From Investing Activities	$8.945M	597.8K	-$17.06M
Cash From Financing Activities	-$97.12K	467.6K	$55.92M
Net Change In Cash	-$8.463M	-9.680M	$448.4K
YoY Change	-52.66%	8611.53%	-104.41%
FREE CASH FLOW
Cash From Operating Activities	-$17.31M	-$10.75M	-$38.41M
Capital Expenditures	$61.31K	$295.9K	$327.3K
Free Cash Flow	-$17.37M	-$11.04M	-$38.74M
YoY Change	66.9%	75.72%	57.62%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40274273	shares
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.74
CY2023	us-gaap	Cost Of Revenue CostOfRevenue		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-34673
CY2023	dei	Entity Registrant Name EntityRegistrantName	CORMEDIX INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-5894890
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	300 Connell Drive
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 4200
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Berkeley Heights
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07922
CY2023	dei	City Area Code CityAreaCode	(908)
CY2023	dei	Local Phone Number LocalPhoneNumber	517-9500
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.001 Par Value
CY2023	dei	Trading Symbol TradingSymbol	CRMD
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	180000000.0	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	54981102	shares
CY2023	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	688
CY2023	dei	Auditor Name AuditorName	Marcum llp
CY2023	dei	Auditor Location AuditorLocation	Marlton, New Jersey
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43642684	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43148323	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	77453	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	124102	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	32388130	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	15644062	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2106345	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	353574	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	11016	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	882214	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	623672	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	79450400	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	59551175	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1866224	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1609679	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	103055	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	102320	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	640278	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	775085	usd
CY2023Q4	us-gaap	Assets Assets	82059957	usd
CY2022Q4	us-gaap	Assets Assets	62038259	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4279679	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2202149	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6970217	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3973941	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	150619	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	134801	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11400515	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6310891	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	517013	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	667632	usd
CY2023Q4	us-gaap	Liabilities Liabilities	11917528	usd
CY2022Q4	us-gaap	Liabilities Liabilities	6978523	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	181622	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	181622	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	181622	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	181622	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	182	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	182	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	160000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	160000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54938258	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54938258	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42815196	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	42815196	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	54938	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	42815	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	94108	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	82743	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	391693214	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	330294782	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-321700013	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-275360786	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	70142429	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	55059736	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	82059957	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	62038259	usd
CY2022	us-gaap	Revenues Revenues	65408	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	3734	usd
CY2022	us-gaap	Gross Profit GrossProfit	61674	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13155125	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10679549	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	35802663	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	20006093	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	48957788	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	30685642	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-48957788	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-30623968	usd
CY2023	us-gaap	Interest Income Other InterestIncomeOther	2681851	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	326016	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-28994	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	37145	usd
CY2023	us-gaap	Interest Expense InterestExpense	34296	usd
CY2022	us-gaap	Interest Expense InterestExpense	26515	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2618561	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	336646	usd
CY2023	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-46339227	usd
CY2022	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-30287322	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-585617	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-46339227	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-29701705	usd
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	9683	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	5055	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1682	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-9442	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	11365	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-4387	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-46327862	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29706092	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.91
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.74
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50902931	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40274273	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	62798067	usd
CY2022	crmd	Stockissuedinconnectionwith At Msaleofcommonstocknet StockissuedinconnectionwithATMsaleofcommonstocknet	17769616	usd
CY2022	crmd	Stock Issued In Connection With Warrants Exercised Cash StockIssuedInConnectionWithWarrantsExercisedCash	128625	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	4069520	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-4387	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-29701705	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	55059736	usd
CY2023	crmd	Stockissuedinconnectionwith At Msaleofcommonstocknet StockissuedinconnectionwithATMsaleofcommonstocknet	12949110	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	42878399	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	287738	usd
CY2023	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-198443	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	5493751	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	11365	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-46339227	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	70142429	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-46339227	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-29701705	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	5493751	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	4069520	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	134807	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	124420	usd
CY2023	us-gaap	Depreciation Depreciation	70755	usd
CY2022	us-gaap	Depreciation Depreciation	84618	usd
CY2022	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-42143	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2106345	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-3008	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	600983	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-187235	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2077479	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-6566	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2995084	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	961963	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-134801	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-121368	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38409480	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24356732	usd
CY2023	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	77084385	usd
CY2022	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	31140004	usd
CY2023	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	60350000	usd
CY2022	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	27650000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	327300	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	219360	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-17061685	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3709364	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	12949110	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	17769616	usd
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	42878399	usd
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	198443	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	128625	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	287738	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	55916804	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	17898241	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2808	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-8677	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	448447	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10176532	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	43374745	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53551277	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	43823192	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	43374745	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	34296	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	26516	usd
CY2023	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	9683	usd
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	5055	usd
CY2023	crmd	Initial Licensing Fee InitialLicensingFee	325000	usd
CY2010Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	73107	shares
CY2023	crmd	Maximum Amount Of Cash Payments Upon Achievement Of Milestones MaximumAmountOfCashPaymentsUponAchievementOfMilestones	3000000	usd
CY2023	crmd	Remaining Balance Of Cash Payments Upon Achievement Of Milestones RemainingBalanceOfCashPaymentsUponAchievementOfMilestones	2000000	usd
CY2023Q4	us-gaap	Reinsurance Retention Policy Reinsured Risk Percentage ReinsuranceRetentionPolicyReinsuredRiskPercentage	0.71	pure
CY2023	crmd	Hospital Stay Charge HospitalStayCharge	17111	usd
CY2023	crmd	Percentage Of Anticipated Wholesaler PercentageOfAnticipatedWholesaler	0.75	pure
CY2023	crmd	Acquisition Cost Price AcquisitionCostPrice	1170	usd
CY2023	crmd	Average Price AveragePrice	1170	usd
CY2023	crmd	Price Of Per Wholesale Acquisition Cost PriceOfPerWholesaleAcquisitionCost	249.99
CY2023	crmd	Percentage Of Transitional Drug Addon Payment Adjustment PercentageOfTransitionalDrugAddonPaymentAdjustment	1	pure
CY2023	crmd	Percent Of Wholesale Acquisition Price PercentOfWholesaleAcquisitionPrice	1	pure
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-321700000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-46300000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-29700000	usd
CY2023Q4	us-gaap	Liquidation Basis Of Accounting Accrued Costs To Dispose Of Assets And Liabilities LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities	104400000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America <span>(“GAAP”)</span> requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43642684	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43148323	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	180508	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	226422	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	43823192	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	43374745	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	64920279	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1425	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	10506	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	64929360	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	22956564	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	4140	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	3537	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	22955961	usd
CY2023	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	1682	usd
CY2022	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-9442	usd
CY2023Q4	crmd	Cash Reimbursed CashReimbursed	47000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	77000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	124000	usd
CY2023Q4	crmd	Longterm Restricted Cash LongtermRestrictedCash	103000	usd
CY2023Q4	us-gaap	Other Inventory OtherInventory	6407266	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1525420	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	580925	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2106345	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1866224	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1609679	usd
CY2023Q4	us-gaap	Property Plant And Equipment Other Accumulated Depreciation PropertyPlantAndEquipmentOtherAccumulatedDepreciation	520542	usd
CY2022Q4	us-gaap	Property Plant And Equipment Other Accumulated Depreciation PropertyPlantAndEquipmentOtherAccumulatedDepreciation	449787	usd
CY2023	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-46339227	usd
CY2022	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-30287322	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11814174	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10110769	shares
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-393207	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-313559	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2270022	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	514354	usd
CY2023Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	2718770	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	2180581	usd
CY2023Q4	crmd	Manufacturing Development Current ManufacturingDevelopmentCurrent	1835101	usd
CY2022Q4	crmd	Manufacturing Development Current ManufacturingDevelopmentCurrent	1214550	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	146324	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	64456	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6970217	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3973941	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-45946020	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-29973763	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	53614000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	47683000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	4603000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	1592000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	6000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	10000	usd
CY2023Q4	crmd	Deferred Tax Assets Capitalized Licensing Fees DeferredTaxAssetsCapitalizedLicensingFees	165000	usd
CY2022Q4	crmd	Deferred Tax Assets Capitalized Licensing Fees DeferredTaxAssetsCapitalizedLicensingFees	304000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	6151000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5270000	usd
CY2023Q4	crmd	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Accrued Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsAccruedCompensation	720000	usd
CY2022Q4	crmd	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Accrued Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsAccruedCompensation	172000	usd
CY2023Q4	crmd	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Section Capitalization DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSectionCapitalization	5522000	usd
CY2022Q4	crmd	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Section Capitalization DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSectionCapitalization	2702000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	-4000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	28000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	70777000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	57761000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	70777000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	57761000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	13016000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	113600000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.80	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.087	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.043	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.002	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.002	pure
CY2023	crmd	Effective Income Tax Rate Reconciliation Njnol Adjustment EffectiveIncomeTaxRateReconciliationNJNOLAdjustment	0	pure
CY2022	crmd	Effective Income Tax Rate Reconciliation Njnol Adjustment EffectiveIncomeTaxRateReconciliationNJNOLAdjustment	0.019	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.014	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.008	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.281	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.157	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.019	pure
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	57761000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	13050000	usd
CY2023	crmd	Increase Decrease Charged Credited To Oci IncreaseDecreaseChargedCreditedToOCI	-34000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	70777000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	52989000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4804000	usd
CY2022	crmd	Increase Decrease Charged Credited To Oci IncreaseDecreaseChargedCreditedToOCI	-32000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	57761000	usd
CY2021	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	626000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	626000	usd
CY2022	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	586000	usd
CY2022Q4	crmd	Number Of Legal Actions Filed NumberOfLegalActionsFiled	2	pure
CY2023	crmd	Amount Of Initial Licensing Fee AmountOfInitialLicensingFee	325000	usd
CY2023	crmd	Shares Of Equity Of Common Stock SharesOfEquityOfCommonStock	7996	shares
CY2023	crmd	Number Of Shares Released In Escrow NumberOfSharesReleasedInEscrow	7277	shares
CY2023	crmd	Maximum Aggregate Amount Of Cash Payments Due Upon Achievement Of Milestones MaximumAggregateAmountOfCashPaymentsDueUponAchievementOfMilestones	3000000	usd
CY2023	crmd	Balance Of Cash Payments Due Upon Achievement Of Milestones BalanceOfCashPaymentsDueUponAchievementOfMilestones	2000000	usd
CY2022	crmd	Balance Of Cash Payments Due Upon Achievement Of Milestones BalanceOfCashPaymentsDueUponAchievementOfMilestones	2000000	usd
CY2023	crmd	Nd License Agreement NDLicenseAgreement	P60D
CY2020Q3	us-gaap	Payments For Leasing Costs PaymentsForLeasingCosts	17000	usd
CY2023Q4	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	18300000	usd
CY2021Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	104400000	usd
CY2023Q2	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	1500093	shares
CY2022Q2	crmd	Percentage Of First Anniversary Of The Grant Date PercentageOfFirstAnniversaryOfTheGrantDate	0.50	pure
CY2022Q2	crmd	Percentage Of Second Anniversary Of The Grant Date PercentageOfSecondAnniversaryOfTheGrantDate	0.30	pure
CY2022Q2	crmd	Percentage Of Third Anniversary Of The Grant Date PercentageOfThirdAnniversaryOfTheGrantDate	0.20	pure
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y7M6D
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	181622	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	181622	shares
CY2023Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	21291665	usd
CY2022Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	21291665	usd
CY2023	crmd	Percentage Of Common Stock Issued And Outstanding PercentageOfCommonStockIssuedAndOutstanding	0.0999	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.24
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.9
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
CY2020Q3	us-gaap	Payments For Leasing Costs PaymentsForLeasingCosts	17000	usd
CY2023Q4	crmd	Rental Agreement Expense RentalAgreementExpense	400	eur
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	207000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	208000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	668000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	151000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	517000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	803000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	135000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	668000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	640000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	775000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	201000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	199000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y9M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y9M18D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.09	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.09	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	205000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	208000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	211000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	169000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	793000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	125000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	668000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet		usd
CY2023	us-gaap	Gross Profit GrossProfit		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables		usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation		usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials		usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess		usd
CY2022Q4	us-gaap	Inventory Net InventoryNet		usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001410098

Files In Submission

Name	View Source	Status
0001213900-24-021585-index-headers.html	Edgar Link	pending
0001213900-24-021585-index.html	Edgar Link	pending
0001213900-24-021585.txt	Edgar Link	pending
0001213900-24-021585-xbrl.zip	Edgar Link	pending
crmd-20231231.xsd	Edgar Link	pending
ea0201177-10k_cormedix.htm	Edgar Link	pending
ea020117701ex10-17_cormedix.htm	Edgar Link	pending
ea020117701ex23-1_cormedix.htm	Edgar Link	pending
ea020117701ex31-1_cormedix.htm	Edgar Link	pending
ea020117701ex31-2_cormedix.htm	Edgar Link	pending
ea020117701ex32-1_cormedix.htm	Edgar Link	pending
ea020117701ex32-2_cormedix.htm	Edgar Link	pending
ea020117701ex97-1_cormedix.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
crmd-20231231_def.xml	Edgar Link	unprocessable
crmd-20231231_lab.xml	Edgar Link	unprocessable
crmd-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ea0201177-10k_cormedix_htm.xml	Edgar Link	completed
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
crmd-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRMD
CorMedix Inc. Stock $crmd

2024 Q1 Form 10-K Financial Statement

#000121390024021585 Filed on March 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRMD CorMedix Inc. Stock $crmd

2024 Q1 Form 10-K Financial Statement

#000121390024021585 Filed on March 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRMD
CorMedix Inc. Stock $crmd